Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization

Core Insights - Johnson & Johnson's revenue and earnings growth are expected to accelerate due to the successful ramp-up of TREMFYA, which is replacing STELARA after its loss of exclusivity [1] Group 1: Revenue and Earnings Growth - The company is poised for revenue and earnings growth acceleration moving forward [1] - The growth is primarily driven by the successful market entry of TREMFYA [1] Group 2: Product Transition - TREMFYA is effectively replacing STELARA, indicating a strategic shift in the company's product lineup [1]